RxDoctor Payments Data

Jody Plaisance, MD

Family Medicine · Thibodaux, LANPI 1588657878

Payments from drug & device makers

$8,099in general payments, 2019–2025

Across 465 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$782
  • GSK$570
  • Pfizer$563
  • Amgen$451
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$8,099100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,099 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$253,237
Medicare patients
719
Services billed
8,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide116$128,961
JardianceEmpagliflozin117$106,989
OzempicSemaglutide75$80,107
FarxigaDapagliflozin Propanediol83$68,934
JanuviaSitagliptin Phosphate45$53,304
EliquisApixaban61$48,683
RybelsusSemaglutide16$31,900
TrulicityDulaglutide24$22,939
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$21,723
Soliqua 100-33Insulin Glargine/Lixisenatide16$17,510
ShingrixVaricella-Zoster Ge/As01b/Pf68$14,498
LinzessLinaclotide14$13,737
XareltoRivaroxaban14$12,091
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$10,112
TradjentaLinagliptin12$6,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$418$151,900140 claims
Boehringer IngelheimJardiance, Tradjenta$161$113,188129 claims
Novo NordiskOzempic, Rybelsus$782$112,00791 claims
AstraZenecaFarxiga$1,096$68,93483 claims
MerckJanuvia$179$53,30445 claims
PfizerEliquis$563$48,68361 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$570$39,816112 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$175$17,51016 claims
AbbVieLinzess$1,758$13,73714 claims
Johnson & JohnsonXarelto$242$12,09114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Thibodaux

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →